See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Community Videos on Diabetes Health TV

Continuous Glucose Monitoring with DEXCOM's

Deb Ruppert

Continuous Glucose Monitoring with DEXCOM's "The Seven"

Dr. Sheri Colberg Interviewed by Scott King

Dr. Sheri Colberg

Dr. Sheri Colberg Interviewed by Scott King

Carol speaks about the Diabetes Health Box Program

Carol Waldrop

Carol speaks about the Diabetes Health Box Program

Novo Nordisk

Page 5
Novo Nordisk Introduces New Industry Resource for Information on Diabetes and Chronic Disease
Apr 4, 2010 | 
Novo Nordisk, a global healthcare company and leader in diabetes care, announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.
FDA Hedges Approval of Long-Acting Byetta, Asks Amylin for More Information
Mar 29, 2010 | 
The U.S. Food and Drug Administration has withheld approval of Bydureon, the once-weekly version of the popular type 2 diabetes drug Byetta.  The agency has asked its manufacturer, Amylin, for more information regarding Bydureon's manufacture, labeling, and risk management plan. It did not, however, request further information on tests of the drug itself-an indication that the agency probably intends to grant marketing permission once it has dotted all the i's and crossed all the t's involved in the approval process.
DHTV
Popular
Top Rated

Related Community Videos on Diabetes Health TV

Continuous Glucose Monitoring with DEXCOM's

Deb Ruppert

Continuous Glucose Monitoring with DEXCOM's "The Seven"

Dr. Sheri Colberg Interviewed by Scott King

Dr. Sheri Colberg

Dr. Sheri Colberg Interviewed by Scott King

Carol speaks about the Diabetes Health Box Program

Carol Waldrop

Carol speaks about the Diabetes Health Box Program

Amylin Hopes to Begin U.S. Sales of Long-Acting Byetta Early This Year
Mar 4, 2010 | 
Amylin Pharmaceuticals has announced that it expects to begin selling a once-weekly version of its diabetes drug, Byetta, by the end of the year. The company reports that the FDA is nearing final inspections of its manufacturing plant and could give the go-ahead for U.S. sales in early March.
FDA Gives Novo the Go-Ahead to Market Victoza® in the U.S.
Feb 27, 2010 | 
Danish pharmaceutical company Novo Nordisk has received Food and Drug Administration permission to begin marketing its type 2 drug Victoza® in the United States.
Victoza, the brand name for liraglutide, is a GLP-1* analog that is taken one a day by injection to help control blood sugar-and in some cases, help with weight loss-in patients with type 2 diabetes.
Diabetes and Pre-Diabetes Cost the U.S. $218 Billion in 2007: En Route to $336 Billion by 2034
Feb 3, 2010 | 
A study commissioned by healthcare company Novo Nordisk has reported that the cost of diabetes and pre-diabetes to the U.S. economy in 2007 was $218 billion. The study, conducted by The Lewin Group, projected that by 2034, the two conditions will cost the economy $336 billion per year.
Novo Nordisk's Victoza Receives FDA Approval for the Treatment of Type 2 Diabetes
Jan 28, 2010 | 
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza (liraglutide injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
Novo Enters Phase 1 Test of an Insulin Pill
Dec 24, 2009 | 
Denmark-based Novo Nordisk A/S has begun phase 1 testing of an insulin pill that, if successful, could replace injections as the primary means of blood sugar control for millions of people with type 1 and type 2 diabetes. The company has enrolled 80 volunteer German test subjects in the study and expects to have preliminary results by the first half of 2011. The test group consists of both people with diabetes and people without it.
Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.